Potential for protein kinase C inhibitors in cancer therapy.
Philip
P A
PA
Division of Hematology and Oncology, Harper Hospital, Detroit, MI 48201, USA.
Harris
A L
AL
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D054713:Bryostatins; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D004351:Drug Resistance; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D018942:Macrolides; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors* / Q000502:physiology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D000970:Antineoplastic Agents; D054713:Bryostatins; D004791:Enzyme Inhibitors; D007783:Lactones; D018942:Macrolides; C046785:bryostatin 1; D011493:Protein Kinase C; D004264:DNA Topoisomerases, Type I; D013755:Tetradecanoylphorbol Acetate